Search

Joan Massagué, Chair of the Cancer Biology and Genetics Program in the Sloan Kettering Institute, has been named the recipient of two prestigious awards.

… Friday, May 1, 2009 Summary Joan Massagué, Chair of the Cancer Biology and Genetics Program in the Sloan Kettering Institute, has been named the recipient of two prestigious awards. Joan Massagué , Chair of the Cancer Biology and Genetics Program in the Sloan Kettering Institute , has been named the

Research led by Josie Robertson Investigator Karuna Ganesh provided clues that microbiomes might explain the increase in colorectal cancer among younger patients.

… Wednesday, April 19, 2023 At a worldwide gathering of the American Association for Cancer Research (AACR), Memorial Sloan Kettering Cancer Center (MSK) scientists presented new insights into the connection between cancer and the gut microbiome, often referred to as the “forgotten organ.” Their findings

A leader in developing better treatments for a range of blood cancers, Dr. Omar Abdel-Wahab is only the second person from MSK to receive the Paul Marks Prize for Cancer Research. 

… Monday, December 1, 2025 For more than two decades, physician-scientist Omar Abdel-Wahab, MD , has been known around Memorial Sloan Kettering Cancer Center (MSK) for his insight, knowledge, and creativity as a cancer researcher.   Now he will also be known as a Paul Marks Prize winner , the first recipient

Andy Minn, MD, PhD, will return to Memorial Sloan Kettering Cancer Center (MSK) as the inaugural Chair of MSK’s new Immuno-Oncology Program in August.

… Thursday, May 15, 2025 Andy Minn, MD, PhD, will return to Memorial Sloan Kettering Cancer Center (MSK) as the inaugural Chair of MSK’s new Immuno-Oncology Program in August. This is a full-circle moment for Dr. Minn, a renowned physician-scientist, who completed his postdoctoral training with  Joan Massagué

Memorial Sloan Kettering Cancer Center has announced that Oren Cahlon, MD, a renowned radiation oncologist and expert in proton therapy, will assume the position of Associate Deputy Physician-in-Chief for the Memorial Sloan Kettering Regional Care Network. With this appointment, which is effective immediately, Dr. Cahlon will help oversee the network’s outpatient clinical programs, which span seven locations across New York and New Jersey.

… Friday, November 23, 2018 Memorial Sloan Kettering Cancer Center has announced that Oren Cahlon, MD , a renowned radiation oncologist and expert in proton therapy, will assume the position of Associate Deputy Physician-in-Chief for the Memorial Sloan Kettering Regional Care Network. With this appointment

Memorial Sloan Kettering Cancer Center (MSK) announced today that the US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation to cobimetinib in treatment of patients with histiocytic neoplasms (HN) (Erdheim-Chester Disease, Rosai-Dorfman, Langerhans Histiocytosis), who do not harbor the BRAF V600 mutation. Cobimetinib is an oral inhibitor of MEK1 and MEK2 currently approved to treat melanoma. This designation was granted based on data submitted by MSK, in collaboration with Genentech, a member of the Roche Group, from a phase II trial of single-agent cobimetinib for adults with histiocytic disorders (published in Nature in March 2019 by Eli Diamond, MD; Omar Abdel-Wahab, MD; and David Hyman, MD).

… Wednesday, October 2, 2019 Bottom Line: Memorial Sloan Kettering Cancer Center (MSK) announced today that the US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation to cobimetinib in treatment of patients with histiocytic neoplasms (HN) (Erdheim-Chester Disease, Rosai-Dorfman

A Black community leader seeks prompt treatment for prostate cancer, avoiding the harsh toll the disease often takes on men like him.

… Thursday, November 2, 2023 Prostate cancer takes a severe toll on Black men.   Prompt diagnosis and treatment is especially important for good outcomes. Larry Scott Blackmon was stunned when actor Chadwick Boseman passed away from colon cancer in August 2020. Several months later, Larry’s annual checkup

New results from a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK), gastrointestinal oncologists Andrea Cercek, MD, and Luis Diaz Jr., MD, demonstrates how immunotherapy alone can allow people with MMRd cancers to avoid surgery and preserve their quality of life.

… Sunday, April 27, 2025 CHICAGO —   New results from a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK), gastrointestinal oncologists  Andrea Cercek, MD , and  Luis Diaz Jr., MD, demonstrate how immunotherapy alone can allow people with  MMRd cancers to avoid surgery and preserve their

Women want to understand and decrease their risk of breast cancer, and Nicole Saphier, MD, Director of Breast Imaging at MSK Monmouth, wants to ensure that women make the right decisions when it comes to their breast health this October, in honor of Breast Cancer Awareness Month, and every day.

… Tuesday, October 23, 2018 Women want to understand and decrease their risk of  breast cancer ,  and Nicole Saphier, MD , Director of Breast Imaging at  MSK Monmouth , wants to ensure that women make the right decisions when it comes to their breast health this October, in honor of Breast Cancer Awareness

Total neoadjuvant therapy is a viable treatment strategy for patients with locally advanced rectal cancer and is associated with the potential to sidestep surgical treatment.

… Monday, September 10, 2018 Total neoadjuvant therapy is a viable treatment strategy for patients with locally advanced rectal cancer and is associated with improved delivery of planned therapy, increased downstaging, earlier introduction of optimal systemic chemotherapy to address micrometastases, and